Bicara Therapeutics (NASDAQ:BCAX) COO Sells $817,641.72 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 28,214 shares of the company’s stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $28.98, for a total transaction of $817,641.72. Following the completion of the sale, the chief operating officer directly owned 182,177 shares in the company, valued at $5,279,489.46. This trade represents a 13.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Thursday, July 9th, Ryan Cohlhepp sold 536 shares of Bicara Therapeutics stock. The stock was sold at an average price of $29.00, for a total transaction of $15,544.00.
• On Friday, May 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $20.29, for a total transaction of $253,625.00.
• On Wednesday, April 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $23.01, for a total transaction of $287,625.00.

Bicara Therapeutics Price Performance

NASDAQ BCAX opened at $28.91 on Monday. Bicara Therapeutics Inc. has a 1 year low of $9.47 and a 1 year high of $30.99. The company has a market capitalization of $1.90 billion, a PE ratio of -10.40 and a beta of -0.81. The company has a fifty day moving average of $23.43 and a 200 day moving average of $20.11.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.21). Research analysts expect that Bicara Therapeutics Inc. will post -3.48 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on BCAX. Cantor Fitzgerald reissued an “overweight” rating on shares of Bicara Therapeutics in a report on Wednesday, May 27th. HC Wainwright raised their price objective on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Citizens Jmp reaffirmed a “market outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a report on Tuesday, March 31st. Wedbush reiterated an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Finally, Wall Street Zen raised shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, May 24th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $30.27.

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC raised its position in Bicara Therapeutics by 26.2% during the first quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock worth $66,350,000 after acquiring an additional 692,933 shares during the period. Rock Springs Capital Management LP lifted its holdings in Bicara Therapeutics by 14.0% during the first quarter. Rock Springs Capital Management LP now owns 489,095 shares of the company’s stock valued at $9,728,000 after purchasing an additional 60,000 shares in the last quarter. Quantinno Capital Management LP grew its position in shares of Bicara Therapeutics by 16.1% in the first quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock valued at $350,000 after purchasing an additional 2,447 shares during the period. Orbimed Advisors LLC grew its position in shares of Bicara Therapeutics by 219.1% in the first quarter. Orbimed Advisors LLC now owns 667,300 shares of the company’s stock valued at $13,273,000 after purchasing an additional 458,200 shares during the period. Finally, Siren L.L.C. increased its stake in shares of Bicara Therapeutics by 11.2% during the first quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock worth $115,421,000 after purchasing an additional 586,001 shares in the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.